CEL-SCI Corp. (NYSE:CVM) focuses on finding innovative ways to activate the immune system to fight cancer and infectious diseases. The company’s leading investigational therapy, Multikine (Leukocyte Interleukin, Injection), is currently being studied in a pivotal phase 3 clinical trial as a potential neoadjuvant treatment for patients with squamous cell carcinoma of the head and neck. If the study reveals a 10% improvement in the overall survival of subjects, then the results will be used to support applications for commercial global marketing approvals. For more information, visit the company’s website at www.cel-sci.com.